Sorry, you need to enable JavaScript to visit this website.
Skip to main content
 

Search

ACR 2020 Newsroom

ACR 2020 Newsroom
Janssen Immunology R&D
ACR 2020 Newsroom
Janssen Immunology R&D

Welcome to the Janssen Immunology ACR 2020 Newsroom! Below, please find the latest for our meeting news, a message from our leaders, social feeds, and more information about our progress and commitment to developing innovative medicines for rheumatologic diseases,
including psoriatic arthritis.

Janssen's Commitment to Rheumatologic Disease
A Message from our Rheumatology Leaders

Dear All,

We are honored to be sharing our latest research in rheumatologic diseases at American College of Rheumatology (ACR) Convergence 2020. At Janssen Immunology, we remain steadfast in our commitment to address unmet need, uncover novel treatment approaches, and work collaboratively to deliver transformational therapies for patients living with these chronic autoimmune diseases. We understand that significant unmet need remains in many of these diseases, including psoriatic arthritis, and that many patients around the world are struggling to find the right treatment, maintain symptom relief, and achieve remission. These patients are the motivating force that drives us to continue to pioneer in rheumatology research, and to ultimately achieve our vision to restore health for all patients with immune-mediated diseases.

Learn more about our research at ACR below and hear directly from our leaders!

Alyssa Johnsen, M.D.
Disease Area Leader
Rheumatology
View Alyssa's profile
 

June Lanoue
Disease Area Commercial Leader
Rheumatology & Dermatology
View June's profile
 

 

Latest News

 

About Psoriatic Arthritis

 

Psoriatic arthritis (PsA) is a chronic, immune-mediated inflammatory disease characterized by peripheral joint inflammation, enthesitis, dactylitis, axial disease and the skin lesions associated with psoriasis.1

Studies show that up to 30 percent of people with psoriasis also develop PsA.2 The disease causes pain, stiffness and swelling in and around the joints; it commonly appears between the ages of 30 and 50, but can develop at any time.2 Nearly half of patients with PsA experience moderate fatigue and about 30 percent suffer from severe fatigue.3 Though the exact cause of PsA is unknown, genes, the immune system and environmental factors are all believed to play a role in the onset of the disease.4

Driven by a relentless dissatisfaction with the status quo, we will redefine treatments for immune diseases by delivering transformational and accessible therapies and regimens to patients with autoimmune disease.

Learn more:

 

Follow @JanssenGlobal for more news and information during ACR 2020!

References:

1 Belasco J, Wei N. Psoriatic Arthritis: What is Happening at the Joint? Rheumatol Ther 2019;6:305-315.
2 National Psoriasis Foundation. Statistics. Available at: https://www.psoriasis.org/content/statistics Accessed October 2020.
3 Husted JA, Tom BD, Schentag CT, et al. Occurrence and correlates of fatigue in psoriatic arthritis. Annals of the Rheumatic Diseases 2009;68:1553-1558. https://ard.bmj.com/content/68/10/1553
4 National Psoriasis Foundation. About Psoriatic Arthritis. Available at: https://www.psoriasis.org/about-psoriatic-arthritis. Accessed October 2020.